Study Summary
This trial is testing whether fasting could improve outcomes for obese breast cancer patients receiving chemotherapy.
- Breast Cancer
- Stage 1 Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Ductal Breast Carcinoma In Situ
- HER2-negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Stage 2 Breast Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Through study participation; approximately 6 months
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (Intermittent Fasting)
1 of 1
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: Chemotherapy · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is enrollment for this investigation currently open?
"Affirmative. Clinicaltrials.gov has information that suggests this experiment is presently enrolling volunteers, with the first posting date being July 28th 2022 and the last update occurring on August 2nd 2022. The research project needs to recruit 55 individuals from a single medical location." - Anonymous Online Contributor
What is the scope of recruitment for this research endeavor?
"Affirmative. The particulars of this clinical trial, which was posted on July 28th 2022, are listed as active recruitment status according to information hosted on clinicaltrials.gov. This medical study requires the participation of 55 individuals from a single site." - Anonymous Online Contributor
What risks are associated with undergoing Chemotherapy?
"After careful consideration, the safety rating of chemotherapy was determined to be a 2 due it's status as Phase 2 clinical trial. Thus far, there is sufficient data to suggest that it is safe but not enough evidence to support its efficacy." - Anonymous Online Contributor